Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC
The approval was based on data from the KEYNOTE-091 trial.
Diagnosis & Disease Information
Ready-to-Dilute Pemfexy Gains Additional NSCLC Indication
The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.
Cytalux Approval Expanded to Include Lung Cancer Detection During Surgery
The approval was based on data from the phase 3 ELUCIDATE study.
Krazati Approved for KRASG12C-Mutated Locally Advanced or Metastatic NSCLC
Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.
FDA Passes on Poziotinib for HER2 Exon 20 Insertion Mutation Positive NSCLC
According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required.
Imjudo Plus Imfinzi and Chemotherapy Approved for Metastatic NSCLC
The approval was based on data from a phase 3 POSEIDON study.
Libtayo Plus Chemotherapy Approved as First-Line Treatment for Advanced NSCLC
Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.
Bevacizumab Biosimilar Alymsys Now Available
Alymsys is a vascular endothelial growth factor inhibitor.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
Retevmo Approved for RET-Driven Solid Tumors, NSCLC
The approvals were based on data from the LIBRETTO-001 trial.
